Key result
Genomic analysis links KAT5 to ~57% lower spinal stenosis risk and identifies multiple candidate drugs.
Why the study?
The genetic drivers and cellular mechanisms driving the progression of spinal stenosis remain inadequately understood, necessitating integrative approaches to identify therapeutic targets.
Effect estimate: OR 0.428 (95% CI 0.274-0.667)
p-value: p=0.036
Integrative genomic analysis identified KAT5, TET2, and TAF10 as key target genes for spinal stenosis and proposed candidate drugs for targeted treatment.
Should not change spinal stenosis practice yet; extends genomic causality with hypothesis-generating therapeutic candidates.
Background Spinal stenosis is a common pathological condition characterized by the narrowing of the spinal canal, contributing to substantial morbidity and imposing a significant socioeconomic burden. Despite its clinical importance, the genetic drivers and cellular mechanisms driving its progression remain inadequately understood, necessitating integrative approaches to identify therapeutic targets. Methods This study employed an integrative multi-omics strategy. Initially, summary-data-based Mendelian randomization was conducted using cis-expression quantitative trait loci data from 19,960 genes alongside spinal stenosis genome-wide association study data. Gene-gene interaction networks and colocalization analyses further refined candidate genes. Additionally, single-cell RNA sequencing of spinal tissues was performed to assess cellular enrichment, and molecular docking was employed to screened FDA-approved drugs against prioritized targets. Immunohistochemistry (IHC), Western blot (WB), and quantitative real-time PCR (qRT-PCR) were conducted using tissue samples and primary cells to validate the bioinformatics analysis results. Results SMR analysis identified 45 candidate target genes, which were further narrowed to three key genes including KAT5, TET2, and TAF10 through gene-gene interaction analysis and colocalization. Single-cell RNA sequencing revealed that these genes were predominantly enriched in chondrocytes and monocytes, implicating cellular cross-talk via the TGF-β1– (TGF-βR1 ++ TGF-βR2) pathway, a driver of fibrosis and ossification. Molecular docking identified six high-affinity compounds: Balsalazide and Eltrombopag for KAT5, Magnesium Citrate and Ferric Citrate for TET2, and Piracetam and Deferiprone for TAF10. The expression level of KAT5 and TET10 were both consistent with our SMR analysis in both tissues and primary cells. Conclusion These findings elucidate novel genetic and cellular mechanisms underlying spinal stenosis, highlighting the role of TGF-β pathway in disease progression. The identified compounds offer promising therapeutic interventions, bridging genomic discoveries to clinical applications and paving the way for targeted treatment strategies.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied Spinal stenosis (n=315,577). Target genes (KAT5, TET2, TAF10) was evaluated on Causal association with spinal stenosis (OR 0.428, 95% CI 0.274-0.667, p=0.036). Integrative genomic analysis identified KAT5 (OR 0.428), TET2 (OR 2.060), and TAF10 (OR 1.859) as key causal genes for spinal stenosis, with molecular docking revealing six potential therapeutic drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: